title: Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.
abstract: The treatment of metastatic melanoma has evolved from an era where interferon and chemotherapy were the mainstay of treatments to an era where immunotherapy has become the frontline. Ipilimumab (IgG1 CTLA-4 inhibitor), nivolumab (IgG4 PD-1 inhibitor), pembrolizumab (IgG4 PD-1 inhibitor) and nivolumab combined with ipilimumab have become first-line therapies in patients with metastatic melanoma. In addition, the high prevalence of BRAF mutations in melanoma has led to the discovery and approval of targeted molecules, such as vemurafenib (BRAF kinase inhibitor) and trametinib (MEK inhibitor), as they yielded improved responses and survival in malignant melanoma patients. This is certainly a burgeoning time in immunotherapy drug development, and the aforementioned efforts along with the recent US Food and Drug Administration approval of talimogene laherparepvec (T-VEC), a recombinant oncolytic herpes virus, have paved the way to exploring the role of additional oncolytic viruses, such as the echovirus Rigvir, as new and innovative treatment modalities in patients with melanoma. Herein, we discuss the current standard of care treatment in melanoma with an emphasis on immunotherapy and oncolytic viruses in development.
authors.affiliation: University of Arizona Cancer Center.
authors.forename: Hani M
authors.initials: HM
authors.lastname: Babiker
authors.affiliation: Department of Internal Medicine, University of Arizona, Tucson.
authors.forename: Irbaz Bin
authors.initials: IB
authors.lastname: Riaz
authors.affiliation: Department of Internal Medicine, University of Arizona, Tucson.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Husnain
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ; Department of Molecular Medicine, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: Mitesh J
authors.initials: MJ
authors.lastname: Borad
keywords: Rigvir; melanoma; virotherapy